Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Total Non-Current Liabilities: 2020-2023

Historic Total Non-Current Liabilities for Journey Medical (DERM) over the last 1 years, with Jun 2023 value amounting to $68.3 million.

  • Journey Medical's Total Non-Current Liabilities fell 8.87% to $68.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $68.3 million, marking a year-over-year decrease of 8.87%. This contributed to the annual value of $86.8 million for FY2022, which is 68.11% up from last year.
  • Journey Medical's Total Non-Current Liabilities amounted to $68.3 million in Q2 2023, which was down 21.47% from $86.9 million recorded in Q1 2023.
  • Journey Medical's Total Non-Current Liabilities' 5-year high stood at $96.4 million during Q3 2021, with a 5-year trough of $33.5 million in Q4 2020.
  • In the last 3 years, Journey Medical's Total Non-Current Liabilities had a median value of $78.2 million in 2022 and averaged $77.6 million.
  • Examining YoY changes over the last 5 years, Journey Medical's Total Non-Current Liabilities showed a top increase of 68.11% in 2022 and a maximum decrease of 16.41% in 2022.
  • Journey Medical's Total Non-Current Liabilities (Quarterly) stood at $33.5 million in 2020, then skyrocketed by 54.18% to $51.6 million in 2021, then spiked by 68.11% to $86.8 million in 2022, then dropped by 8.87% to $68.3 million in 2023.
  • Its last three reported values are $68.3 million in Q2 2023, $86.9 million for Q1 2023, and $86.8 million during Q4 2022.